“A federal advisory panel declined Wednesday to vote on how Johnson & Johnson’s Covid-19 vaccine should be used, saying it needs more time to gather information on the risk of the shot following reports of cases of rare but severe blood clots that developed in a few recipients,” the Wall Street Journal reports.
Politico: States fret pause in J&J vaccine could drive up hesitancy.
Save to Favorites